Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as part of a corporate rebranding. Its activities have primarily involved research and clinical development in the United States. Synaptogenix has historically traded under the Nasdaq symbol SNPX; the symbol TAOX may not correspond to the company.

Key Stats

• Today's Range: $4.21 to $4.40
• 50-Day Range: $3.22 to $4.80
• 52-Week Range: $3.07 to $10.00
• Volume: 66,025 shs
• Average Volume: 156,437 shs
• Market Capitalization: $31.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 2% of companies evaluated by MarketBeat, and ranked 895th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Synaptogenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Synaptogenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.04% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 2.53, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Synaptogenix has recently increased by 33.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.70% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

10.34% of the stock of Synaptogenix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TAOX
• Previous Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: www.taosynergies.com
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.74 million
• Net Margins: -2,153.97%
• Pretax Margin: -2,153.97%
• Return on Equity: -128.51%
• Return on Assets: -97.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.98
• Quick Ratio: 19.98

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 106.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.83 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 7,480,000
• Free Float: 7,281,000
• Market Cap: $31.92 million
• Optionable: N/A
• Beta: 1.49